This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Amgen Shares Have the Right Prescription for Long-Term Growth

NEW YORK (TheStreet) -- You will be hard-pressed to find a stronger name than Amgen (AMGN - Get Report) in the biotech/pharma space.

The stock closed Friday at $122.84, up 0.47%; by noon on Monday they were down another 0.7% to $121.99. Shares are up just shy of 7% on the year to date, trailing the health care sector's 13% gain. The company reports second-quarter earnings on Tuesday.

Investors are unsure of what to make of the stock, which doesn't appear to present any long-term value. To those skeptics, I say, let's widen the scope.

Read More: It May Be Tech's Turn; A Genuinely Nutty Idea: Jim Cramer's Best Blogs

With a price-to-earnings ratio of close to 20, Amgen doesn't cheap to some. But in the near-term, Amgen should continue to benefit from efficient cost controls and stable market share gains. The company's management has done and will continue to do exactly what they were told they couldn’t -- manage growth and profits. This has become the perfect formula for a higher stock price.

This means that around $122 per share, Amgen stock can still do well for investors looking for exposure in the biotech space. On the basis of improving cash flow and positive clinical trial data, these shares should reach $130 by the end of the year and $135 in the next six to 12 months.

The trailing P/E of 20 may not present an obvious value, but on a forward-looking basis, that P/E drops to 14. So I wouldn't consider the stock expensive until it reaches at least $130, which is still 6% above current value.

And even assuming Amgen does report a strong quarter on Tuesday, investors still may not realize the company's true value until one to two years down the line. This is because Amgen recently disclosed successful results for its phase-3 thyroid drug product AMG 416. It was discovered that the drug met both primary and secondary endpoints for hyperparathyroidism.

With close to 13 million people being affected by hyperparathyroidism (kidney failure), AMG 416 can become a lucrative drug for Amgen in the coming years.

Read More: Another Heavy Earnings Week on Tap, as Pfizer, UPS, 5 Others Set to Report

What's more, due to expanding margins, the company is consistently growing its operating income. Analysts underestimated the extent to which management would reconcile prior concerns about Amgen's competitive position -- particularly in terms of its pipeline. That, plus stronger capital expense controls for three consecutive quarters, places Amgen in the top tier of profit generators within the sector.

Regarding the pipeline, there is still the threat from the likes of Teva Pharmaceuticals (TEVA), which is working on a rival product to Amgen's cancer drug Neulasta. For that matter, advances made from companies like Gilead (GILD) and Celgene (CELG) are keeping Amgen investors awake at night.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMGN $162.59 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs